In medical terms, CIS stands for carcinoma in situ, a condition where abnormal cells that resemble cancer are found only in the place where they first formed. These cells have not spread into surrounding tissue. CIS is classified as stage 0 disease, meaning it sits at the earliest possible point on the cancer spectrum.
What “In Situ” Actually Means
“In situ” is Latin for “in its original place.” The term describes abnormal cells that are still contained within the thin layer of tissue where they developed. Every organ in the body has a structural boundary called the basement membrane, a sheet of proteins that separates surface tissue from deeper layers. In carcinoma in situ, abnormal cells have not broken through that membrane. Once they do, the diagnosis changes from CIS to invasive cancer, which carries the potential to spread to lymph nodes and distant organs.
This distinction matters because CIS and invasive cancer behave very differently. Non-invasive carcinomas confined to the surface side of the basement membrane are classified as benign in terms of their current behavior. Invasive cancers, by contrast, have broken through that barrier and can metastasize to the lungs, liver, bones, or brain. The basement membrane is the single most important line pathologists look for when deciding whether a biopsy shows stage 0 disease or something more advanced.
Where CIS Is Most Commonly Found
CIS can develop in many organs, but three locations account for most diagnoses: the breast, the bladder, and the skin.
Breast (DCIS)
Ductal carcinoma in situ, or DCIS, is the most widely discussed form of CIS. It involves abnormal cells growing inside the milk ducts of the breast without invading surrounding breast tissue. Today, 20% to 25% of all breast cancer diagnosed in the United States is DCIS. That proportion has risen sharply over time. Before routine screening mammography, fewer than 5% of new breast cancer diagnoses were DCIS.
The reason for the jump is straightforward: DCIS rarely produces a lump you can feel. About 90% of cases are detected on screening mammograms, where they typically show up as tiny clusters of calcium deposits. Linear or branching patterns of these calcifications are especially suspicious for DCIS. Without mammography, many of these cases would go undetected until (or unless) they progressed to invasive cancer.
Bladder
CIS of the bladder looks and behaves quite differently from the more familiar papillary bladder tumors that grow on stalks into the bladder cavity. Bladder CIS is flat, making it difficult to see during a cystoscopy (a camera exam of the bladder lining). It is always considered high grade, with a 50% to 75% risk of becoming invasive if left untreated. That makes it one of the more aggressive forms of CIS, despite being technically stage 0.
Skin (Bowen’s Disease)
Squamous cell carcinoma in situ of the skin is often called Bowen’s disease. It appears as a slightly raised, scaly, reddish patch with an irregular border, usually a single lesion. Under a microscope, the abnormal cells occupy the full thickness of the outermost skin layer but have not invaded the deeper layer beneath it. Risk factors include heavy sun exposure, immunosuppression, arsenic exposure, and HPV infection.
How Likely CIS Is to Become Invasive
The progression risk varies significantly by location and type. For breast DCIS, studies of untreated cases suggest that 25% to 60% progress to invasive ductal carcinoma within 9 to 24 years of follow-up. Those numbers come from older studies with small sample sizes (cases where biopsies were initially misread and patients went untreated), so they represent a rough range rather than a precise prediction.
Bladder CIS carries a higher short-term risk. Without treatment, 50% to 75% of cases become invasive. Low-grade papillary bladder tumors, by comparison, become invasive only about 10% of the time. For skin CIS, progression to invasive squamous cell carcinoma is possible but generally slower, particularly when the lesion is identified and treated early.
The key takeaway is that CIS is not a guaranteed path to cancer. Some cases never progress. But because there is no reliable way to predict which ones will, most CIS diagnoses are treated rather than watched.
How CIS Is Treated
Treatment for CIS focuses on removing or destroying the abnormal cells before they have a chance to become invasive. The approach depends on where the CIS is located.
For breast DCIS, the two main surgical options are lumpectomy (removing just the affected area) or mastectomy (removing the entire breast), sometimes with reconstruction. Lumpectomy is often followed by radiation therapy to the whole breast to reduce the chance of recurrence. Because DCIS has not spread beyond the ducts, lymph node removal is generally not necessary, though a sentinel node biopsy is sometimes performed with mastectomy.
Bladder CIS is typically treated with a medication delivered directly into the bladder through a catheter, a process that stimulates the immune system to attack the abnormal cells. Skin CIS can often be treated with surgical removal, freezing, or topical creams that trigger a local immune response against the abnormal cells.
What a CIS Diagnosis Means for You
A CIS diagnosis can feel alarming because the word “carcinoma” is in the name. But stage 0 is fundamentally different from later-stage cancer. The abnormal cells are contained. They have not invaded deeper tissue, entered blood vessels, or reached lymph nodes. Treatment outcomes for CIS are generally excellent, particularly for breast DCIS, where survival rates after treatment approach nearly 100% at five years.
That said, CIS does require follow-up. After treatment for DCIS, for example, there is a small ongoing risk of recurrence in the same breast or development of invasive cancer later. Regular imaging and clinical exams are a standard part of long-term monitoring. The same principle applies to bladder CIS, where recurrence is common enough that periodic cystoscopy exams continue for years after initial treatment.
If you see “CIS” or “carcinoma in situ” on a pathology report, it means the abnormal cells were caught at their earliest, most treatable stage, before they crossed the boundary that separates contained disease from cancer that can spread.